4 unchanged sentences
Holders of Record
−Removed: As of close of business on February 11, 2021, there were 92 holders of record of our common stock.
+Added: As of close of business on January 21, 2022, there were 21 holders of record of our common stock.
The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.
5 unchanged sentences
Stock Price Performance Graph
−Removed: As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide this information.
+Added: The following performance graph and related information shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into any other filings under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing.
+Added: The graph below compares the cumulative total stockholder return on $100 invested in our common stock with the cumulative total return of $100 invested in the Nasdaq Composite Index and the Nasdaq Biotechnology Index from the close of market on July 24, 2020, which was our initial trading day, through November 30, 2021, assuming the reinvestment of dividends, if any.
+Added: The comparisons shown in the graph below are based upon historical data and are not necessarily indicative of, nor intended to forecast, the potential future performance of our common stock.
+Added: $100 investment in stock or index
+Added: Nurix Therapeutics, Inc.
+Added: NASDAQ Composite Index
+Added: NASDAQ Biotechnology Index
Use of Proceeds from Registered Securities
−Removed: In the third fiscal quarter of 2020, we completed our IPO and sold 12,550,000 shares of common stock at an offering price of $19.00 per share.
−Removed: The offer and sale of all of the shares in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No.
−Removed: 333-239651), which was declared effective by the SEC on July 23, 2020.
−Removed: No additional shares were registered.
−Removed: There has been no material change in the planned use of proceeds from our IPO as described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on July 24, 2020.
+Added: On July 23, 2020, our registration statement on Form S-1, as amended (File No.
+Added: 333-239651), was declared effective by the SEC in connection with the initial public offering (IPO) of our common stock.
+Added: There has been no material change in the planned use of proceeds from our IPO as described in the final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on July 24, 2020.
Securities Authorized for Issuance under Equity Compensation Plans
1 unchanged sentence
Unregistered Sales of Equity Securities
−Removed: From December 1, 2019 through November 30, 2020, we sold and issued the following unregistered securities:
−Removed: Prior to filing our registration statement on Form S-8 in July 2020, we issued and sold to our directors, officers, employees, and consultants an aggregate of 447,177 unregistered shares of common stock upon exercise of stock options under our 2012 Equity Incentive Plan at per share exercise prices ranging from $0.24 to $9.57.
−Removed: In March 2020, we issued 9,431,364 shares of Series D redeemable convertible preferred stock that resulted in gross proceeds of $120.2 million.
−Removed: The offers, sales and issuances of the securities described in paragraph (1) above were deemed to be exempt from registration under the Securities Act under Rule 701 promulgated under the Securities Act as offers and sale of securities pursuant to certain compensatory benefit plans and contracts relating to compensation in compliance with Rule 701.
−Removed: The offers, sales and issuances of the securities described in paragraph (2) above were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act.
−Removed: The recipients of securities in this transaction acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in this transaction.
−Removed: Each of the recipients of securities in this transaction was an accredited or sophisticated person and had adequate access, through employment, business or other relationships, to information about us.
Purchases of Equity Securities by Issuers and Affiliated Purchasers
−Removed: The table below provides information with respect to recent repurchase of unvested shares of our common stock:
−Removed: Total Number of Shares Purchased ( 1)
−Removed: Average Price Paid per Share
−Removed: Total Number of Shares Purchased as part of Publicly Announced Plans or Programs
−Removed: Maximum Number of Shares that May Yet Be Purchased Under the Plans or Program
−Removed: September 1 – September 30, 2020
−Removed: October 1 – October 31, 2020
−Removed: November 1 – November 30, 2020
−Removed: All of the shares repurchased, as reflected in the table above, were repurchases of unvested shares of our common stock that had been issued upon early exercise of stock options.
−Removed: Upon termination of employment of a person holding unvested shares, we are entitled to repurchase the unvested shares.
−Removed: Selected Financial Data
−Removed: As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide this information.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.